Erectile dysfunction (ED) is associated with clinical atherosclerosis and several atherosclerotic risk factors including smoking, hypertension, dyslipidemia, diabetes mellitus, obesity and sedentary lifestyle. Clinical atherosclerosis is also associated with these same risk factors and with biomarkers of inflammation, thrombosis, endothelial cell activation.We evaluated the crosssectional association between the degree of ED and levels of atherosclerotic biomarkers. A subcohort of 988 US male health professionals between the ages 46 and 81 years as part of an ongoing epidemiologic study had atherosclerotic biomarkers measured from blood collected in 1994-1995. These same men had in 2000, been retrospectively asked about erectile function in 1995 and in 2000. Biennial questionnaires since 1986 assessed medical conditions, medications, smoking, physical activity, body mass index, alcohol intake. The retrospective assessment of erectile function in 2000 for 1995 in these 988 men ranged from very good -28.2%, good -25.1%, fair -19.2%, poor -13.6%, to very poor -13.9%. Men with poor to very poor erectile function compared to men with good and very good erectile function had 2.9 the odds of having elevated Factor VII levels (P ¼ 0.03), 1.9 times the odds of having elevated vascular cell adhesion molecule (P ¼ 0.13) and 2.0 times the odds of having elevated intracellular adhesion molecule (P ¼ 0.06) and 2.1 times the odds of having elevated total cholesterol/high-density lipoprotein ratio (P ¼ 0.02) comparing the top to bottom quintiles for each atherosclerotic biomarker after multivariate adjustment. Lipoprotein(a), homocysteine, interleukin-6 and tumor necrosis factor receptor, C-reactive protein and fibrinogen were not associated with the degree of erectile function after adjustment. We conclude that selected biomarkers for endothelial function, thrombosis and dyslipidemia but not inflammation are associated with the degree of ED in this cross-sectional analysis. Future studies evaluating the prospective association of ED, endothelial function and cardiovascular disease appear warranted.
Introduction
The inability to achieve and/or maintain an erection, known as erectile dysfunction (ED) is a common condition in adult males affecting over 30 million men in the United States. 1 Previously we have reported in this cohort that retrospectively assessed moderate to severe ED was found in 12% of men younger than age 59 years; 22% of men aged 60-69 years and 30% of men older than age 69 years. 2 Although ED is a multifactorial process, vascular disease of the penile arteries is an important cause of ED accounting for up to 80% of cases. [3] [4] [5] The nitric oxide-cyclic guanosine-3 0 5 0 -monophosphate system is important in producing and sustaining an erection. Smooth muscle relaxation is brought about by the release of nitric oxide from both vascular endothelial cells and neural tissue supplying the corpora cavernosa. Abnormalities in this vasodilator system are present in atherosclerosis and also in ED. [6] [7] [8] Subjects with ED have increased prevalence of coronary artery disease and peripheral vascular disease. 9, 10 There is a significant correlation between the severity of ED and the number of affected coronary vessels involved in subjects with coronary artery disease. 11 ED is most strongly associated with traditional coronary heart disease (CHD) risk factors such as age, hypercholesterolemia, hypertension, cigarette smoking, physical inactivity, obesity and with diabetes mellitus. 2, 12 Recently, it has been suggested that rather than cardiovascular disease and its treatment being a risk factor for ED, instead ED may be a harbinger of CHD in asymptomatic men. 4, 9, [11] [12] [13] [14] [15] It has been suggested that endothelial dysfunction is linked to ED as they share a dependence on a common pathway through the release of nitric oxide. [16] [17] [18] [19] Endothelial dysfunction may be an early marker for the presence of subclinical atherosclerosis. 20 Early forms of endothelial dysfunction are believed to be a marker for atherosclerosis as well as an indicator of the susceptibility to develop cardiovascular disease. 21 Although it is not clear whether endothelial dysfunction is simply related to decreased bioavailability of nitric oxide or its increased degradation owing to oxidative stress or a combination of these factors, individuals with manifest CHD as well as subclinical cardiovascular disease show evidence of depressed endothelial function in the coronary artery as well as in the other arterial beds.
Based upon this preliminary work in selected clinical populations, we were interested in determining whether the degree of ED was associated with measures of endothelial cell activation, inflammation, thrombosis and atherosclerosis in a large cohort study of health professionals. We hypothesized that increasingly severe ED would be associated with increasing levels of biomarkers associated with endothelial cell activation, inflammation, thrombosis and dyslipidemia.
Methods

Participants
The Health Professionals Follow-up Study (HPFS) is a cohort of male dentists, optometrists, osteopaths, podiatrists, pharmacists and veterinarians in the United States who responded to a mailed survey in 1986. Follow-up surveys are mailed every 2 years. At the time of the 2000 questionnaire, 43 235 men aged 53-90 years were alive and participating in the study. We received 34 282 surveys (response rate of 79%) after three repeat mailing to nonresponders. We excluded subjects with prostate cancer, penile implants and testosterone therapy because ED in these instances is related to therapy or other nonvascular causes. We also excluded those who did not respond to the question regarding ED (n ¼ 2514), leaving 31 768 men who had erectile function assessed. In 1994-1995, 18 225 of the subjects in the cohort had blood drawn. Subjects with blood drawn did not differ from other participants without blood drawn. A subset of 988 men who had biomarkers for atherosclerosis measured as part of a nested case-control study of myocardial infarction 22 (n ¼ 593) or a cross-sectional study of biomarkers of alcohol consumption 23 (n ¼ 408) and had erectile function ascertained are the focus of this report.
Outcome measures Erectile dysfunction. In 2000, subjects were asked to rate their ability without treatment to have and maintain an erection good enough for intercourse for the time periods 1995 or later, and for the last 3 months. Response options included very poor, poor, fair, good and very good. Additional questions about desire, ability to reach orgasm and usual quality of erections were also asked. We did not ask about the frequency or opportunity for intercourse; psychosocial function; partner discord or heterosexual, homosexual or bisexual preference. Single question assessment of ED has been used in this and other population cohorts with reasonable face validity.
2,24
Age, sociodemographic variables, health behaviors, comorbid conditions and medications. Participants provided information on age, weight, smoking status, medications and physical activity. If weight was missing, we used the weight recorded on the previous questionnaire. Body mass index (BMI) was calculated as the weight in kilogram per height in meters squared. Self-reported weights have been previously shown to be highly correlated with technician measured weights (r ¼ 0.97) in this cohort. 25 Physical activity was assessed using a validated 10-item questionnaire. 26 Response options included 13 categories ranging from none to 40 or more hours per week of leisure time activities. Metabolic equivalents (METS) were assigned to each type of activity and metabolic equivalents per week were calculated based upon the amount of time participants spent in each activity. History of cardiovascular disease, high blood pressure, high blood cholesterol and cancer were determined by self-reports preceding the blood collection. Alcohol intake was estimated using a Willett dietary questionnaire in 1994. 27 Relationship between biomarkers of atherosclerosis and ED CB Eaton et al Atherosclerotic biomarkers. Between 1994 and 1995 each subject was sent a blood collection kit containing instructions and necessary supplies for blood drawing (blood tubes, tourniquet and needles). The participants made their own individual arrangements for phlebotomy. Time since the proceeding meal and date and time of phlebotomy was recorded. Blood was collected in three 10-ml ethylene diaminetetraacetic acid tubes, placed on icepacks stored in Styrofoam containers and sent via overnight courier. Over 95% of samples were received within 24 h. After receipt, samples were centrifuged, aliquoted into plasma, erythrocytes and buffy coat and stored in the gas phase of liquid nitrogen storage freezers at temperatures below À1301C. All biomarkers assays were carried out on Hitachi 911 analyzer (Roche Diagnostics, Indianapolis, IN, USA). The total cholesterol (TC), triglycerides and high-density lipoprotein (HDL) concentrations were run using standard assays from Roche Diagnostics (Indianapolis, IN, USA). The coefficient of variation (CV) defined as the standard deviation divided by the mean Â 100 is a measure of the precision of an assay. The CV for lipids is o1.8%. C-reactive protein (CRP) was measured using an immunoturbidimetric assay with reagents and calibrators from Denka Seiken (Niigata, Japan) that had CV o6%. Fibrinogen was measured with an immunoturbidimetric assay using reagents and calibrators from Kamiya Biomedical (Seattle, WA, USA) with a CV of 2.6%. Soluble intracellular adhesion molecules (sICAM), soluble vascular cell adhesion molecules (sVCAM), interleukin-6 (IL-6) and plasma soluble fractions tumor necrosis factor-a receptors 1 and 2 (sTNFR1, sTNFR2) were measured by enzyme-linked immunosorbent assay (ELISA) from R&D Systems (Minneapolis, MN, USA) with CV ranging from 8.7 to 9.3%. Lipoprotein(a) (Lp(a)) was determined by a latex-enhanced immunoturbidimeteric method (Denka Sieken, Tokyo Japan) with a CV of 2.6%. Homocysteine was measured by highpressure liquid chromatography with fluorometric detection; the intralaboratory CV was 3.3% for 7 mmol/l and 2.9% for 12 mmol/l. Factor VII was determined by ELISA with CV of 3.0%.
Statistical analysis
We conducted cross-sectional analyses of ED and a wide range of atherosclerotic biomarkers. We determined age-adjusted partial Spearman's correlation coefficients using generalized linear modeling to determine age-adjusted least-square (LS) means for the relationship between biomarkers and ED. This allows for all levels of erectile function to be assessed in relation to each biomarker. For those atherosclerotic biomarkers that demonstrated a meaningful age-adjusted cross-sectional association with the degree of ED, we proceeded to more advanced statistical models to determine the independence of the association adjusting for age (continuous), marital status (currently married, divorced, widowed, never married), TV viewing time (h/week), smoking status (never, past, current), BMI (o20, 20-24.9, 25-29.9 and X30 kg/m 2 ), alcohol (g/day, 0, 0.1-4.9, 5-14.9, 15-29.9, X30) and physical activity metabolic equivalents (METS). We also further adjusted comorbid medications and chronic diseases associated with ED including history of high blood pressure (yes or no), diabetes (yes or no), hypercholesterolemia (yes or no) and medication use (yes or no, any medication of antidepressants, finasteride, b-blockers, a-blockers, thiazide diuretics or cholesterol-lowering medication) and history of coronary artery disease. We used a mixed random effects generalized linear modeling procedure to evaluate the independent association between atherosclerotic biomarkers as the independent variables and degree of erectile function as the dependent variable (1 ¼ very poor to 5 ¼ very good function). We also evaluated atherosclerotic biomarkers modeled as quintiles as the independent variables adjusting for sociodemographic variables, health behaviors and comorbid medications and diseases to predict ED dichotomized as 'very poor' and 'poor' compared to 'good' and 'very good'. The logistic regression was used to estimate the odds ratios of ED comparing each quintiles of biomarkers to the bottom quintile. To test for linear trend, we used the median biomarker levels in the quintiles as a continuous variable. The P-values in Table 3 are based upon this test for linear trend. All P-values presented are two-tailed and P-values below 0.05 were considered statistically significant. All analyses were performed using SAS 8.2 (SAS Institute, Cary, NC, USA).
Results
Self-reported erectile function in 1995 in this subcohort ranged from very good -28.2%, good -25.1%, fair -19.2%, poor -13.6% to very poor -13.9%. The range of ED 5 years later in the same group shifted downwards to very good -21.7%, good -19.2%, fair -16.6%, poor -14.3%, very poor -25.3% showing progression of ED with age as expected.
As can be seen in Table 1 , subjects with very poor erectile function were older, less likely to be currently married, more sedentary, had less moderate alcohol intake, had higher levels of hypertension, hypercholesterolemia, CHD and were more likely on b-blockers. These men were also less likely to be on antidepressants than those with good and very good erectile function. To look for graded relationships between the degree of ED and atherosclerotic biomarkers, we evaluated the age-adjusted Relationship between biomarkers of atherosclerosis and ED CB Eaton et al LS means and partial Spearman's correlations for markers of endothelial cell activation -ICAM, VCAM; thrombosis -Factor VII, fibrinogen; dyslipidemia -TC/HDL ratio, triglycerides, HDL cholesterol, non-HDL cholesterol; inflammation -CRP, IL-6, TFNR1, TFNR2; and nontraditional risk factors -homocysteine and Lp(a) (see Table 2 ). For those biomarkers that showed an association with increasing severity of ED, we evaluated the independent effect adjusting for known associations Abbreviations: BMI, body mass index; ED, erectile dysfunction.
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with ED in this cohort (age, physical inactivity, BMI, alcohol use), history of hypertension, hypercholesterolemia, smoking, medications, cardiovascular disease and cancer. The associations that persisted as independent predictors of ED after adjusting for socio-demographic factors, traditional cardiovascular risk factors, medications and co-morbid medical conditions were: sICAM (P ¼ 0.009), sVCAM (P ¼ 0.05), Factor VII (P ¼ 0.04); triglycerides (P ¼ 0.004), TC/HDL (P ¼ 0.03), with increasing levels of each biomarker associated with increasing levels of ED. To more easily discuss these associations, we present in Table 3 three models. Model 1 is the age-adjusted model; Model 2 is the age, sociodemographic and health behavior-adjusted model and Model 3 is the fully adjusted model including medication use and chronic diseases. We compared the top quintile to the bottom quintile of each biomarker and defined ED as 'very poor' and 'poor' erectile function compared to 'good' and 'very good'. Compared to the lowest quintile, the upper quintile of Factor VII was associated with 2.9 (95% confidence interval (CI) 1.0, 8.4) times the odds of ED. For a similar comparison of extreme quintiles for markers of endothelial dysfunction, VCAM and ICAM were associated with 1.9 (95% CI 0.9, 4.1) and 2.0 (95% CI 0.9, 4.2) times, respectively, the odds of ED. For dyslipidemia, elevated levels of TC/ HDL and triglycerides were associated with 2.1 (95% CI 1.1,3.9) and 1.8 (95% CI 1.0, 3.2) times, respectively, the odds of ED compared to lower levels. There was a modest interaction by age with Factor VII and ICAM demonstrating a stronger association in the over age 65 strata, and VCAM, triglycerides, HDL cholesterol demonstrating a stronger association for the under age 65 strata, but none of these interactions reached statistical significance.
Discussion
This study demonstrates, in a cross-sectional analysis of men 46-81 years of age, that selected biomarkers for endothelial function, thrombosis and dyslipidemia, but not biomarkers of inflammation or Lp(a) or homocysteine, are associated with the degree of ED even after adjusting for age, CHD risk factors, incident CHD and medications. Our findings of a relationship between the degree of endothelial cell activation and ED are consistent with a small but growing literature evaluating endothelial dysfunction using a variety of techniques. A recent study by Kaiser et al., 28 examined measures of endothelial function in 57 men; moderate to severe ED (n ¼ 30) and with minimal to no ED (n ¼ 27), who had no overt risk factors for or history of CHD. They found no difference between ED cases and controls in terms of subclinical atherosclerosis such as carotid intimal medial wall thickness, coronary calcification score by ultra-fast computed tomography scan, but did find a marked difference in endothelial-dependent and -independent flow-mediated vasodilatation of the brachial Relationship between biomarkers of atherosclerosis and ED CB Eaton et al artery. Recently, Chiurlia et al. 29 compared endothelial function, coronary artery calcification and CRP in 70 subjects with ED from an endocrine clinic compared with 73 controls subjects recruited by advertisement, and found that subjects with ED had higher CRP (2.62 vs 1.03), impaired flow mediated dilation (2.36 vs 3.92) and more coronary artery calcification than control patients.
Bocchio et al. 30 recently demonstrated that subjects with ED and no associated CHD risk factors (n ¼ 45) had statistically significant (Po0.01) elevated biochemical measures of endothelial function, *P-value: P-value for test for linear trend, we used the median biomarker levels in each quintile as a continuous variable.
Relationship between biomarkers of atherosclerosis and ED CB Eaton et al that is, sVCAM-1, sICAM-1 and sE-selectin compared to controls (n ¼ 25). Also, Esposito et al. 31 in a randomized-controlled trial showed that obese men with ED who underwent a weight loss and increased physical activity program over a 2-year period had improvement in erectile function and endothelial function as measured by L-arginine response compared to controls. This study suggests that the link between ED and endothelial dysfunction may be reversible.
We found a weak association between fibrinogen and the degree of ED in the age-adjusted analysis which was attenuated in multivariate analysis, and no association with Lp(a). This compares to the small study by Sullivan et al. 32 of 138 patients that found an association with fibrinogen but not with Lp(a).
We found an association of triglycerides and TC/HDL ratio but not TC and the degree of ED. This compares to the results of Fung et al. 33 who evaluated the prospective association of cardiovascular risk factors and onset of ED 25 years later in the Rancho Bernardo study, and found a significant association of elevated cholesterol and triglycerides and the risk of ED.
The HPFS was not originally designed to evaluate ED, and thus questions regarding erectile function in 1995 were determined by recall in 2000 and thus prone to recall bias. In addition, erectile function was evaluated by a single question. These are important limitations to this study. However, a single question evaluating erectile function similar to the question used has been used in most epidemiologic studies of ED and appears comparable in its reliability to more extensive questionnaires. 24, 33 In addition, this question has been used to evaluate the prevalence and incidence of ED in our large prospective cohort with strong associations with age, smoking, physical activity, alcohol use and diabetes, thus demonstrating good face validity. 2, 34 The misclassification bias or measurement error introduced by us using a single retrospectively ascertained question about erectile function should lead to random misclassification, which should bias our results towards the null, thus leading to an underestimation of the association between erectile function and atherosclerotic biomarkers if a perfect measure of erectile function was available. Therefore, some of the null finding such as ours not finding an association between erectile function and inflammatory biomarkers such as CRP and IL-6 may be spurious owing to this misclassification bias. However, our findings of an association between erectile function and Factor VII, VCAM, ICAM and lipids are possibly underestimated.
Another potential limitation of this study is the potential for selection bias of our analytic cohort. Our analytic cohort is not a random sample from the entire cohort but we merged two subcohorts from the HPFS where we had measured a large array of biomarkers. We compared this group with both the larger cohort where we had erectile function data and the sample where blood samples had been drawn, and found little difference in sociodemographic, comorbid conditions or health behaviors and therefore believe that this is reasonable sample to test this association between erectile function and atherosclerotic biomarkers. Some of the analytic cohort developed CHD over the subsequent 5 years, which is known to be associated with atherosclerotic biomarkers and may have confounded our results. We attempted to analyze such confounding bias in two ways. First, we adjusted our analysis for incident CHD in our multivariate advanced statistical models and continued to show strong statistically significant results. Second, we removed the incident CHD subjects from our analysis (data not shown) and repeated the analysis in this smaller cohort and found the same strength of association between erectile function and levels of Factor VII, VCAM, ICAM, TC/HDL ratio and triglycerides but with reduced statistical precision. These findings suggest that our results cannot be explained by confounding bias of incident CHD.
This study demonstrates a biologically relevant cross-sectional relationship between selected biomarkers associated with atherosclerosis, that is, endothelial function, thrombosis, dyslipidemia and the degree of erectile function even after adjusting for age, sociodemographic and traditional CHD risk factors. Whether modification of these risk factors leads to improvement in these biomarkers and improvement in ED remains largely untested but is a plausible hypothesis based upon our research findings. Indeed, a small study by Saltzman et al. 35 demonstrated significant improvement in erectile function in nine hypercholesterolemic men receiving atorvastatin for an average of 3.7 months.
A second largely unanswered question is whether ED can serve as a sentinel prospective marker for CHD. Given the relatively strong association of ED and endothelial cell activation in this study and the strong prospective association of endothelial dysfunction and CHD, this is a plausible hypothesis. Indeed, Thompson et al. 15 recently tested this hypothesis in a large prospective cohort of men and found that incident or prevalent ED was associated with a 45% increased risk of subsequent cardiovascular events. Further analysis of this relationship in other cohorts is needed. last authors made all the final decisions regarding the design, conduct and reporting of the study and the decision to submit the manuscript for publication.
